Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-04-20
2009-11-24
Nickol, Gary B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S232100, C424S184100, C424S185100, C530S300000
Reexamination Certificate
active
07622120
ABSTRACT:
A vaccine for preventing or treating Orthopoxvirus infection that induces a protective or therapeutic immune response, wherein the vaccine comprises (1) an amino acid sequence of 20 amino acid or less (preferably 12 amino acid or less and most preferably 11 amino acid or less) of the formula X1-SEQ ID NO:1-X2, wherein X1and X2are peptides of 0-11 amino acid in length comprising either native or non-native amino acid sequences, (2) an antigen-presenting cell pulsed with the peptide, or (3) a cell sensitized in vitro to the peptide is disclosed.
REFERENCES:
Berhanu et al., Vaccination of BALB/c Mice withEscherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge, 2008, Journal of Virology, vol. 82, No. 7, pp. 3517-3529.
CDC Smallpox Report, Published Mar. 31, 2003.
Genbank Accession # AAG37665, published Jul. 30, 2002.
Rodriguez-Ortega et al., Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome, Nature Biotechnology, Feb. 2006, 24(2), 191-7. Epublished Jan. 15, 2006.
Meiring et al., Stable isotope tagging of epitopes: a highly selective strategy for the identification of major histocompatibility complex class I-associated peptides induced upon viral infection, Molecular and Cellular Proteomics, May 2006, 5(5), 902-13. Epublished Jan. 23, 2006.
Meiring et al., Mass tag-assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4+ T lymphocytes, Journal of Immunology, May 1, 2005, 174(9), 5636-43.
Flyer at al, DC, Identification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product, Infection and Immunity, Jun. 2002, 70(6), 2926-32.
Van Els et al., A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains, European Journal of Immunology, Apr. 2000, 30(4), 1172-81.
Herr et al., Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4 (+) or CD8(+) T lymphocytes from human blood, Proceedings of the National Academy of Science U S A. , Oct. 12, 1999, 96(21), 12033-8.
Tsai et al., Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes, Journal of Clinical Investigation, Jan. 15, 1996, 97(2), 577-84.
Tsomides et al., Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1, Journal of Experimental Medicine, Oct. 1, 1994 180(4), 1283-93.
Johnson Kenneth L.
Muddiman David C.
Ovsyannikova Inna G.
Poland Gregory A.
Blumel Benjamin P
Mayo Foundation for Medical Education and Research
Nickol Gary B
Quarles & Brady LLP
LandOfFree
Peptide originating from vaccinia virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide originating from vaccinia virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide originating from vaccinia virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4109583